Elgendy Hamed, El Moghazy Walid M, Nafady-Hego Hanaa, Uemoto Shinji
From the Department of Anesthesia, Assiut University, Assiut, Egypt; and the Department of Anesthesia, King Abdullah Medical City, Mecca, Saudi Arabia.
Exp Clin Transplant. 2015 Apr;13 Suppl 1:100-7.
The outcome of children who had living-donor liver transplant was analyzed according to their status before transplant, and we analyzed the outcome of critically ill patients.
This was a retrospective analysis of children who received primary living-donor liver transplant at Kyoto University Hospital. According to the criteria of the United Network for Organ Sharing, we divided patients into 3 groups: Group A patients had been admitted to the intensive care unit before living-donor liver transplant; Group B patients were hospitalized but did not require intensive care unit stay; and Group C patients were living at home and underwent elective transplant.
A total 685 patients met inclusion criteria. Children in Group A were younger than Group B and received liver grafts from younger donors than Group B and C. Group A patients had marked impairment in liver and renal function and coagulation profile and needed higher volumes of fresh frozen plasma transfusions. Group A patients had significantly worse outcomes and early patient death than the other group; Group A patient survival was 68.3%, 63.2%, 60.1%, and 56.1% at 1, 5, 10, and 15 years after living-donor liver transplant (P < .0001). Group A had worse graft survival than other groups (P < .0001), and Group A graft survival was 68.3%, 65.9%, 54.1%, and 49.9% at 1, 5, 10, and 15 years. Low gamma-glutamyl transpeptidase was an independent risk factor for patient death in Group A (hazard ratio, 1.004; 95% confidence interval, 1.0-1.007) (P < .05). Group A patients had a higher rate of multidrug-resistant hospital-acquired infections.
Children who were admitted to the intensive care unit prior to living-donor liver transplant had marked impairment of pretransplant laboratory parameters and worse outcome than other groups.
根据活体肝移植患儿移植前的状况分析其预后,并分析危重症患者的预后。
这是一项对在京都大学医院接受初次活体肝移植患儿的回顾性分析。根据器官共享联合网络的标准,我们将患者分为3组:A组患者在活体肝移植前入住重症监护病房;B组患者住院但无需入住重症监护病房;C组患者居家并接受择期移植。
共有685例患者符合纳入标准。A组患儿比B组患儿年龄小,接受的肝脏移植物供体比B组和C组的供体年龄小。A组患者的肝肾功能、凝血指标明显受损,需要输注更多量的新鲜冰冻血浆。A组患者的预后明显比其他组差,早期患者死亡率也更高;活体肝移植后1年、5年、10年和15年,A组患者的生存率分别为68.3%、63.2%、60.1%和56.1%(P < .0001)。A组的移植物生存率比其他组差(P < .0001),1年、5年、10年和15年时A组移植物生存率分别为68.3%、65.9%、54.1%和49.9%。低γ-谷氨酰转肽酶是A组患者死亡的独立危险因素(风险比,1.004;95%置信区间,1.0 - 1.007)(P < .05)。A组患者多重耐药医院获得性感染的发生率更高。
活体肝移植前入住重症监护病房的患儿移植前实验室指标明显受损,预后比其他组差。